# A Phase II Study of AK146D1 in Combination With AK112 in Advanced Non-Small Cell Lung Cancer

Source: https://onco.cc/trials/nct07669779/  
OnCo record `nct07669779` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of AK146D1, Ivonescimab, Osimertinib in non-small-cell lung cancer and small-cell lung cancer, run by Akeso, now recruiting.

## Summary

A Phase II Study of AK146D1 in Combination With AK112 in Advanced Non-Small Cell Lung Cancer is a phase 2 interventional study registered as NCT07669779 by Akeso, with 348 participants planned, started 2026-07-10 and due to reach its primary completion in 2027-08-30. Interventions recorded: AK146D1 for injection, AK112 Injection, Platinum chemotherapy, Osimertinib. Conditions listed: Advanced Non Small Cell Lung Cancer (NSCLC). No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT07669779
- Phase: 2
- Setting: A Phase II Clinical Study Evaluating the Safety, Tolerability, Pharmacokinetics and Antitumor Efficacy of AK146D1 in Combination With AK112 or Other Anticancer Therapies in Patients With Advanced Non-Small Cell Lung Cancer
- Sponsor: Akeso
- Enrolled: 348

## Sources

- ClinicalTrials.gov NCT07669779: https://clinicaltrials.gov/study/NCT07669779

## Connected records

- cancers: [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/), [Small-cell lung cancer](https://onco.cc/cancers/sclc/)
- drugs: [AK146D1](https://onco.cc/drugs/ak146d1/), [Ivonescimab](https://onco.cc/drugs/ivonescimab/), [Osimertinib](https://onco.cc/drugs/osimertinib/)
- companies: [Akeso](https://onco.cc/companies/akeso/)

---
JSON: https://onco.cc/api/v1/entities/nct07669779.json